Valuation dashboard for Cardiff Oncology, Inc. (CRDF) with P/E N/A, P/B 3.63, EV/EBITDA -1.93 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Analysis Summary
Cardiff Oncology, Inc. reported revenue of $593000 in the most recent fiscal year, growing at a 5-year CAGR of 10.1%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -83.2%, net margin -78.8%.
At the current price of $1.35, CRDF has negative trailing earnings (P/E not meaningful) and an ROE of -103.08%. Market capitalisation stands at $104M.
Balance sheet quality for CRDF: current ratio of 3.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.63 |
| EV / EBITDA | -1.93 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | $104M | 3.63 | -103.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.35 |
| Market Cap | $104M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -103.08% |
| Return on Invested Capital | -156.60% |
| Return on Assets | -107.29% |
| Gross Margin | 100.00% |
| Operating Margin | -8320.08% |
| Net Margin | -7884.06% |
Related companies: APLT · CRBP · ELTX · FBRX · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of CRDF: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks